Am J Perinatol 2014; 31(11): 983-986
DOI: 10.1055/s-0034-1370348
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Remifentanil Analgesia during Laser Treatment for Retinopathy of Prematurity: A Practical Approach in Neonatal Intensive Care Unit

Nihal Demirel
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Ahmet Y. Bas
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Sumru Kavurt
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Istemi H. Celik
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Husniye Yucel
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Dursun Turkbay
1  Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Emre Hekimoğlu
2  Department of Ophthalmology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara, Turkey
,
Orhan Koc
3  Department of Health Politics, Turkish Ministry of Health, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

07 December 2013

24 December 2013

Publication Date:
02 May 2014 (online)

Abstract

Background Retinopathy of prematurity (ROP) is a significant cause of childhood blindness.

Aim The aim of this study is to determine the feasibility of remifentanil analgesia during laser treatment of ROP performed in the neonatal intensive care unit (NICU).

Patients and Methods Remifentanil was infused continuously during the procedure starting with a dose of 0.2 µg/kg/min and increased gradually to 0.6 µg/kg/min to provide an adequate level of analgesia.

Results We enrolled 64 infants. Remifentanil was infused continuously at a mean rate of 0.4 ± 0.1 μg/kg/min. No major adverse effects were observed except in two patients with reversible bradycardia and hypotension. Premature infant pain profile (PIPP) scores revealed no pain. Patients with bronchopulmonary dysplasia had similar remifentanil dosage, intubation duration, and extubation time.

Conclusions Remifentanil analgesia for ROP treatment performed in the NICU by pediatricians is a safe and effective modality. This modality offers a practical solution in hospitals without readily available pediatric anesthetists.